Estrella Immunopharma announces annual shareholder meeting

Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

ESLA

0.00
  • Estrella Immunopharma will hold its combined 2025/2026 annual shareholder meeting virtually on June 29, 2026.
  • Shareholders will vote on ratifying Macias Gini & O’Connell as independent registered public accounting firm for the year ending Dec. 31, 2026.
  • The audit firm reported audit fees of $197,000 for 2025, versus $128,000 for the six-month transition period ended Dec. 31, 2024.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-023012), on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.